Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00427687 · ClinicalTrials.gov registry record · Phase 1

Study Evaluating AGG-523 in Subjects With Osteoarthritis

A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 1
Development phase

NCT00427687 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00427687, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.

Interventions

  • DRUG AGG-523

Trial Details

FieldValue
Start Date 2007-02
Est. Completion 2007-06
Phase Phase 1

What the Registry Record Tells You About NCT00427687

The ClinicalTrials.gov registry entry for NCT00427687 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which AGG-523 is the first listed.

NCT00427687 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00427687 about?

NCT00427687 is a clinical study titled "Study Evaluating AGG-523 in Subjects With Osteoarthritis". This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.

What is the current status of trial NCT00427687?

This trial is currently completed. It is a Phase 1 study. The study started on 2007-02. Estimated completion is 2007-06.

What interventions are being tested in trial NCT00427687?

The interventions under investigation include: AGG-523 (DRUG).

Who is sponsoring clinical trial NCT00427687?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.